Scienture Holdings, Inc. (SCNX) Form 8-K — Oct 19, 2026
$SCNXForm 8-KItems 2.02, 3.01, 9.01Filed Oct 19, 2026, 4:05 PM ET0001493152-26-047579Original filing
Scienture Holdings (SCNX) announced preliminary unaudited Q3 2026 revenue of approximately $1.22 million, a 256% sequential increase from about $344,000 in Q2 2026. Growth was driven by Arbli™ wholesale unit sales up 74% sequentially and the August 2026 launch and initial wholesale shipments of REZENOPY™, its second FDA-approved product. Management, including Co-CEOs Narasimhan Mani and Shankar Hariharan, said the company is targeting profitability in 2027, citing historically high gross margins and commercial expansion into institutional channels.
Key figures
- Revenue
- 1220000
- Revenue Yoy
- 0
- Q2 2026 revenue
- 344000
- Sequential revenue growth pct
- 256
- Minimum bid price compliance days
- 10
- Arbli wholesale unit sales sequential growth pct
- 74
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.